212 related articles for article (PubMed ID: 31863279)
1. Do microsatellite instability (MSI) and deficient mismatch repair (dMMR) affect the pathologic complete response (pCR) in patients with rectal cancer who received neoadjuvant treatment?
Acar T; Acar N; Kamer E; Tekindal MA; Cengiz F; Kar H; Atahan K; Haciyanli M
Updates Surg; 2020 Mar; 72(1):73-82. PubMed ID: 31863279
[TBL] [Abstract][Full Text] [Related]
2. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
3. Microsatellite instability and response to neoadjuvant chemoradiotherapy in rectal cancer: A systematic review and meta-analysis.
O'Connell E; Reynolds IS; McNamara DA; Prehn JHM; Burke JP
Surg Oncol; 2020 Sep; 34():57-62. PubMed ID: 32891354
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite Instability (MSI) as an Independent Predictor of Pathologic Complete Response (PCR) in Locally Advanced Rectal Cancer: A National Cancer Database (NCDB) Analysis.
Hasan S; Renz P; Wegner RE; Finley G; Raj M; Monga D; McCormick J; Kirichenko A
Ann Surg; 2020 Apr; 271(4):716-723. PubMed ID: 30216221
[TBL] [Abstract][Full Text] [Related]
5. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
[TBL] [Abstract][Full Text] [Related]
6. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
[TBL] [Abstract][Full Text] [Related]
7. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
de Rosa N; Rodriguez-Bigas MA; Chang GJ; Veerapong J; Borras E; Krishnan S; Bednarski B; Messick CA; Skibber JM; Feig BW; Lynch PM; Vilar E; You YN
J Clin Oncol; 2016 Sep; 34(25):3039-46. PubMed ID: 27432916
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
Front Immunol; 2022; 13():913483. PubMed ID: 35958603
[TBL] [Abstract][Full Text] [Related]
9. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
[TBL] [Abstract][Full Text] [Related]
10. Mismatch Repair System Deficiency Is Associated With Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Meillan N; Vernerey D; Lefèvre JH; Manceau G; Svrcek M; Augustin J; Fléjou JF; Lascols O; Simon JM; Cohen R; Maingon P; Bachet JB; Huguet F
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):824-833. PubMed ID: 31404579
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant immunotherapy for dMMR/MSI-H locally advanced rectal cancer: The future new standard approach?
Cabezón-Gutiérrez L; Custodio-Cabello S; Palka-Kotlowska M; Díaz-Pérez D; Mateos-Dominguez M; Galindo-Jara P
Eur J Surg Oncol; 2023 Feb; 49(2):323-328. PubMed ID: 36400657
[TBL] [Abstract][Full Text] [Related]
12. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy.
Shi S; Zhou M; Wang G; Xu J; Zhang D; Zheng M; Zhang S
Cancer Control; 2023; 30():10732748231214936. PubMed ID: 38008773
[TBL] [Abstract][Full Text] [Related]
14. A Predictive Model to Evaluate Pathologic Complete Response in Rectal Adenocarcinoma.
Qing S; Gu L; Du T; Yin X; Zhang KJ; Zhang HJ
Technol Cancer Res Treat; 2023; 22():15330338231202893. PubMed ID: 37750231
[No Abstract] [Full Text] [Related]
15. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Immune Checkpoint Inhibitor Therapy for Patients With Microsatellite Instability-High Colorectal Cancer: Shedding Light on the Future.
Sahin IH; Zhang J; Saridogan T; Gorantla V; Rhree J; Malhotra M; Thomas R; Hsu D; Saeed A
JCO Oncol Pract; 2023 May; 19(5):251-259. PubMed ID: 36862965
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of microsatellite instability in sporadic locally advanced rectal cancer following neoadjuvant radiotherapy.
Du C; Zhao J; Xue W; Dou F; Gu J
Histopathology; 2013 Apr; 62(5):723-30. PubMed ID: 23425253
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite Instability Correlated Inflammatory Markers and their Prognostic Value in the Rectal Cancer Following Neoadjuvant Chemoradiotherapy: A Hypothesis-generating Study.
Lee JH; Kang BH; Song C; Kang SB; Lee HS; Lee KW; Chie EK; Kim JS
In Vivo; 2020; 34(4):2119-2126. PubMed ID: 32606192
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
